Insmed Acquires Phase 2 Ready Monoclonal Antibody INS1148
I'm PortAI, I can summarize articles.
Insmed has acquired INS1148, a Phase 2-ready monoclonal antibody from Opsidio, aimed at treating respiratory, immunological, and inflammatory diseases. INS1148 targets the SCF248 isoform to prevent inflammatory cascades while preserving tissue healing. Insmed plans to develop it for interstitial lung disease and moderate-to-severe asthma. This acquisition marks a significant step in Insmed's clinical development efforts.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments